As South Africa marks 50 years since the June 1976 youth uprising for a dream of freedom, a new generation of young people dreaming of an HIV-free future gave their time, trust, and participation to help deliver a breakthrough new HIV prevention product that was launched this June, writes Ntando Yola.
With a new six-monthly injection, South Africa last week launched the most promising new HIV prevention tool in years, but much of the infrastructure that made HIV prevention services accessible to high-risk groups has been dismantled over the last year. Amy Green asks whether we can successfully deliver this breakthrough technology without the trusted pathways that were decimated by cuts to aid from the United States.
On June 5 2026, an HIV prevention injection will for the first time become available at some of South Africa’s public sector clinics. In this Spotlight special briefing, Marcus Low and Elri Voigt pull together all you need to know about this “breakthrough” jab.
From the limited rollout of a new HIV prevention jab to developments with new weight loss medicines, to high-stakes court cases relating to National Health Insurance (NHI), 2026 is set to be another tumultuous year in healthcare. Here are nine stories that Spotlight will keep a close eye on.
The year’s biggest health story by far has been the cuts to US aid for health and US support for health research. But it’s also been a year of important HIV prevention developments, NHI court cases, ongoing crises in some of our provincial health departments, and some first steps toward accountability for the corruption at Tembisa Hospital.
An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.
A new HIV prevention jab has the potential to bring an end to the AIDS epidemic. But a lack of ambition and unjustifiable secrecy over pricing is holding it back, argue three leading health activists.
An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
Research led by Professor Adrie Bekker is paving the way for an important HIV medicine to be made available to neonates in a way that is both safe and much more convenient than previous options. Biénne Huisman met with the passionate clinician-scientist at her office in Cape Town.
Elzette Rousseau from the Desmond Tutu HIV Foundation told attendees at the top HIV conference in The United States about a project taking HIV prevention services to schools in Cape Town. Biénne Huisman visited one of the sites to find out how it works.
Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
